Phenotypification and Response to Treatment of Allergic Patients with Severe Asthma: Real-World Experience in Argentina
Article Sidebar
Main Article Content
Abstract
Introduction: Evidence on the response to treatment with biologics in allergic patients with severe asthma in Latin America is scarce. Our objective was to compare the baseline phenotype and response to biologic therapy in allergic and non-allergic adult patients in the Argentine cohort of the International Severe Asthma Network (ISAN).
Methods: We analyzed the data available at baseline and at 12 months of biologic treatment in allergic (positive skin test and/or radioallergosorbent test with associated symptoms) and non-allergic patients.
Results: n=79: 51 allergic (64.56%) and 28 non-allergic (35.44%). Allergic patients were significantly younger and had a longer history of asthma at the start of treatment. The median number of asthma exacerbations was significantly reduced in both subgroups, with no differences in the magnitude of the effect. Hospitalizations were significantly reduced in allergic patients, and no hospitalizations were reported in non-allergic patients. The baseline percentage of allergic and non-allergic patients requiring maintenance oral corticosteroids was similar and decreased significantly, with no differences in the magnitude of the decrease. The median ACT (Asthma Control Test) score and FEV1% increased significantly in both subgroups, with no differences in the magnitude of effect. The percentages of clinical remission (4 domains) were similar (25.49% in allergic patients; 25% in non-allergic patients).
Conclusions: Despite demographic phenotypic differences between allergic and non-allergic patients with severe asthma, the response and clinical remission rates with biological agents were comparable in both subgroups.
Downloads
Article Details
Data Availability Statement
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Wang J, Zhou Y, Zhang H, Hu L, Liu J, Wang L et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Sig Transduct Target Ther 2023;8:138. https://doi.org/10.1038/s41392-023-01344-4
Chabra R, Gupta M. Allergic and Environmentally Induced Asthma. [Updated 2023 Aug 7]. In: StatPearls. Treasure Island (FL): StatPearls [Internet]. [Consultado 1 Sep 2025]. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK526018/
Kimura Y, Suzukawa M, Inoue N, Imai S, Akazawa M, Matsui H. Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use. WAOJ 2021;14:100600. https://doi.org/10.1016/j.waojou.2021.100600
Global Initiative for Asthma Global Strategy for Asthma Management and Prevention, updated May 2024. [Internet]. [Consultado 1 Sep 2025]. Disponible en: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 2020;145(3):757-765. https://doi.org/10.1016/j.jaci.2019.12.006
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic Endotypes and Phenotypes of Asthma. Allergy Clin Immunol Pract 2020;8:429-40. https://doi.org/10.1016/j.jaip.2019.11.008
Siroux V, Oryszczyn MP, Paty E, Kauffmann F, Pison C, Vervloet D et al. Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study. Clin Experimental Allergy 2003;33:746-51. https://doi.org/10.1046/j.1365-2222.2003.01674.x
Terl M, Diamant Z, Kosturiak R, Jesenak M. Choosing the right biologic treatment for individual patients with severe asthma – Lessons learnt from Picasso. Resp Med 2024;234:107766. https://doi.org/10.1016/j.rmed.2024.107766
Franchi M, Saldarini F, Brichetti V, Rosenbaum T, Zweiner R, Videla A et al. Clinical remission rates in severe asthma and its predictive factors in a real world setting from Argentina. Eur Resp J 2025; 66(suppl 69): PA5722. https://doi.org/10.1183/13993003.congress-2025.PA5722